These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 18855914)

  • 21. An open source pharma roadmap.
    Balasegaram M; Kolb P; McKew J; Menon J; Olliaro P; Sablinski T; Thomas Z; Todd MH; Torreele E; Wilbanks J
    PLoS Med; 2017 Apr; 14(4):e1002276. PubMed ID: 28419094
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The value of drug repositioning in the current pharmaceutical market.
    Tobinick EL
    Drug News Perspect; 2009 Mar; 22(2):119-25. PubMed ID: 19330170
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Competition: Unlikely partnerships.
    Savage N
    Nature; 2016 May; 533(7602):S56-8. PubMed ID: 27167391
    [No Abstract]   [Full Text] [Related]  

  • 24. Impact of solid state properties on developability assessment of drug candidates.
    Huang LF; Tong WQ
    Adv Drug Deliv Rev; 2004 Feb; 56(3):321-34. PubMed ID: 14962584
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Cohorts and registers: Which public/private partnerships to choose?].
    Jouan-Flahault C; Landais P; Thomas R; Parker S; Genevaz D
    Presse Med; 2012 May; 41 Suppl 1():S15-9. PubMed ID: 22464892
    [No Abstract]   [Full Text] [Related]  

  • 26. Cardiovascular drug discovery: a perspective from a research-based pharmaceutical company.
    Gromo G; Mann J; Fitzgerald JD
    Cold Spring Harb Perspect Med; 2014 Jun; 4(6):. PubMed ID: 24890831
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficient and effective compound management to support lead optimization.
    Johnson CW; Chatterjee M; Kubala S; Helm D; Houston J; Banks M
    J Biomol Screen; 2009 Jun; 14(5):523-30. PubMed ID: 19483145
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug-diagnostic co-development: how to harness the value.
    Blair ED; Blakemore JA
    Drug Discov Today; 2011 Oct; 16(19-20):902-5. PubMed ID: 21888987
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Open-access public-private partnerships to enable drug discovery--new approaches.
    Müller S; Weigelt J
    IDrugs; 2010 Mar; 13(3):175-80. PubMed ID: 20191434
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vertical disintegration: a strategy for pharmaceutical businesses in 2009?
    Dixon J; Lawton G; Machin P
    Nat Rev Drug Discov; 2009 Jun; 8(6):435. PubMed ID: 19483701
    [No Abstract]   [Full Text] [Related]  

  • 31. How can attrition rates be reduced in cancer drug discovery?
    Moreno L; Pearson AD
    Expert Opin Drug Discov; 2013 Apr; 8(4):363-8. PubMed ID: 23373702
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Future pharmaceutical research: the need to look beyond science.
    Seeger S
    Future Med Chem; 2014 May; 6(7):721-3. PubMed ID: 24941866
    [No Abstract]   [Full Text] [Related]  

  • 33. Alcohol medications development: advantages and caveats of government/academia collaborating with the pharmaceutical industry.
    Litten RZ; Ryan M; Falk D; Fertig J
    Alcohol Clin Exp Res; 2014 May; 38(5):1196-9. PubMed ID: 24689461
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systematic risk identification and assessment using a new risk map in pharmaceutical R&D.
    Schuhmacher A; Brieke C; Gassmann O; Hinder M; Hartl D
    Drug Discov Today; 2021 Dec; 26(12):2786-2793. PubMed ID: 34229082
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Microfluidics contribution to pharmaceutical sciences: From drug discovery to post marketing product management.
    Nys G; Fillet M
    J Pharm Biomed Anal; 2018 Sep; 159():348-362. PubMed ID: 30032003
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [PHARMACEUTICAL INDUSTRY AND PERSONALIZED MEDICINE: A PARADIGM SHIFT IN THE DEVELOPMENT OF NEW DRUGS].
    Scheen AJ
    Rev Med Liege; 2015; 70(5-6):237-41. PubMed ID: 26285445
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mergers and innovation in the pharmaceutical industry.
    Comanor WS; Scherer FM
    J Health Econ; 2013 Jan; 32(1):106-13. PubMed ID: 23220457
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predicting Antibody Developability Profiles Through Early Stage Discovery Screening.
    Bailly M; Mieczkowski C; Juan V; Metwally E; Tomazela D; Baker J; Uchida M; Kofman E; Raoufi F; Motlagh S; Yu Y; Park J; Raghava S; Welsh J; Rauscher M; Raghunathan G; Hsieh M; Chen YL; Nguyen HT; Nguyen N; Cipriano D; Fayadat-Dilman L
    MAbs; 2020; 12(1):1743053. PubMed ID: 32249670
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of assay technology as applied to safety assessment in reducing compound attrition in drug discovery.
    Thomas CE; Will Y
    Expert Opin Drug Discov; 2012 Feb; 7(2):109-22. PubMed ID: 22468913
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibiotic research and development: business as usual?
    Harbarth S; Theuretzbacher U; Hackett J;
    J Antimicrob Chemother; 2015; 70(6):1604-7. PubMed ID: 25673635
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.